The Cancer Biology and Genetics (CBG) Program is on a quest to catalyze mechanism-driven science and foster paradigm-shifting cancer concepts. Our labs pursue research bridging basic and clinical cancer science with the goal of improving diagnosis, treatment, and prevention. Our multidisciplinary approach spans areas such as tumor progression and metastasis, tumor microenvironment, mechanisms of drug sensitivity and resistance, and epigenetic sources of tumorigenic traits.

We draw from fundamental mechanisms of cell and tissue development and homeostasis, animal models of disease, and clinical samples in order to enhance our understanding of the biological processes relevant to cancer and to produce or validate new targets that might form the basis of new drugs or therapeutic approaches. Our close alliances with clinicians place us in a unique position, allowing the CBG Program to expedite translational research and make a significant impact on patient care.

 Cancer Biology & Genetics Program Chair Scott Lowe with physician-scientist Karuna Ganesh.

CBG Program Chair Scott Lowe with physician-scientist Karuna Ganesh at the annual retreat sponsored by MSK’s Geoffrey Beene Cancer Research Center.

 

Our Faculty

  • Scott W. Lowe, PhD
    Chair, Cancer Biology & Genetics Program
    Cancer biologist Scott Lowe uses genetically engineered mouse models to study how the genetic alterations in cancer cells contribute to tumorigenesis, alter treatment response, and create molecular vulnerabilities that may be targeted therapeutically.
  • Robert Benezra, PhD
    Cancer biologist Robert Benezra studies the molecular mechanisms of tumor growth and metastatic progression using mouse models. In addition, he studies the spindle assembly checkpoint which ensures proper chromosome segregation and is often deregulated in cancer.
  • Kitai Kim, PhD
    Stem cell biologist Kitai Kim studies epigenetic regulation of DNA methylation in stem cells and cancer.
  • Joan Massagué, PhD
    Sloan Kettering Institute Director Joan Massagué studies the control of stem cell growth and phenotype in tumor progression, metastasis, and response to therapy.
  • Christine Mayr, MD, PhD
    Molecular and cell biologist Christine Mayr studies how 3′UTRs regulate protein functions and how mRNAs contribute to cytoplasmic organization.
  • Luis F. Parada, PhD
    Developmental biologist Luis F. Parada uses genetically engineered mouse models to study neurofibromatosis, brain tumors, cancer stem cells, and tumor progression.
  • Tuomas Tammela, MD, PhD
    Cancer biologist Tuomas Tammela investigates cellular heterogeneity in lung, pancreatic and colon cancers.
  • Craig B. Thompson, MD
    Memorial Sloan Kettering President Craig Thompson studies molecular signaling pathways that regulate nutrient uptake and the role these pathways play in the regulation of cell growth and survival.
  • Andrea Ventura, MD, PhD
    Cancer biologist Andrea Ventura studies non-coding RNAs in cancer and development
  • Hans-Guido Wendel, MD
    Cancer biologist Hans-Guido Wendel pursues both disease-centered and basic discovery research. The disease focus is on lymphocyte malignancies and the basic science arm of the lab explores fundamental mechanisms that control aberrant mRNA translation programs in cancer. Work in these two research areas frequently intersects in surprising ways.
  • Richard White, MD, PhD
    Cancer biologist and oncologist Richard White uses the zebrafish to dissect interactions between tumor cells and the microenvironment that promote metastasis.

Joint Appointees

  • Kenneth Offit, MD
    Cancer geneticist Kenneth Offit focuses on gene characterization; genetic and epidemiologic studies of cancer-predisposing alleles; and the therapeutic, prognostic, and psychosocial translation of these findings.
  • Elli Papaemmanuil, PhD
    Molecular geneticist Elli Papaemmanuil performs systematic interrogations of well annotated clinical trial cohorts in leukemia and cancer to explore how the compound genetic and clonal architecture in patients leukemias and tumors dictate clinical phenotype, disease progression and clinical outcomes.

Collaborations & Resources

SKI offers a wide array of core facilities and other technologies, as well as significant opportunity for collaboration. Scientists in the CBG Program derive particular benefit from close ties to the following:

Join Our Program
We seek out innovative new scientists to join our faculty on an annual basis. Recruitment begins in the fall. Postdocs and other prospective lab members can learn more by browsing the lab pages of individual PIs or by visiting our Careers website.
Learn more
Latest News

View latest research news from the Sloan Kettering Institute.

View all news
Seminars & Events

View events and symposia sponsored by the CBG Program.

View all upcoming events